Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D, metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjeldsen, Sasha A.S., Gluud, Lise L., Werge, Mikkel P., Pedersen, Julie S., Bendtsen, Flemming, Alexiadou, Kleopatra, Tan, Tricia, Torekov, Signe S., Iepsen, Eva W., Jensen, Nicole J., Richter, Michael M., Goetze, Jens P., Rungby, Jørgen, Hartmann, Bolette, Holst, Jens J., Holst, Birgitte, Holt, Joachim, Gustafsson, Finn, Madsbad, Sten, Svane, Maria S., Bojsen-Møller, Kirstine N., Wewer Albrechtsen, Nicolai J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638073/
https://www.ncbi.nlm.nih.gov/pubmed/37953952
http://dx.doi.org/10.1016/j.isci.2023.108190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638073/
https://www.ncbi.nlm.nih.gov/pubmed/37953952
http://dx.doi.org/10.1016/j.isci.2023.108190

Ejemplares similares